Migalastat
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Migalastat: From Fabry Disease to Hepatoportal Sclerosis
One-Sentence Summary
Migalastat is a pharmacological chaperone originally used to treat Fabry disease in patients with amenable GLA gene mutations. The TxGNN model predicts it may be effective for Hepatoportal Sclerosis, but this direction is currently supported by 0 clinical trials and 0 publications, and the identical prediction score shared across the top five ranked indications suggests the result may reflect a knowledge-graph clustering artefact rather than a genuine biological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fabry disease (patients with amenable GLA mutations) — sourced from the repurposing rationale text; no formal indication record was returned |
| Predicted New Indication | Hepatoportal Sclerosis |
| TxGNN Prediction Score | 98.85% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal mechanism-of-action data for migalastat is marked as a data gap in this evidence pack. However, the repurposing rationale indicates migalastat’s known mechanism is as a pharmacological chaperone for α-galactosidase A (α-Gal A), used exclusively in Fabry disease patients with amenable GLA mutations, acting on the lysosomal glycosphingolipid metabolism pathway.
No mechanistic link between this pathway and hepatoportal sclerosis (a vascular/fibrotic liver pathology) has been identified. Notably, the top five ranked predictions for this drug (hepatoportal sclerosis, primitive portal vein thrombosis, hepatopulmonary syndrome, early-onset noncirrhotic portal hypertension, and idiopathic copper-associated cirrhosis) all share the exact same TxGNN score (0.98853…), which strongly suggests these predictions originate from a shared “rare liver disease” node cluster in the graph embedding rather than five independent biological signals. This pattern should be treated as a flag for low confidence, not as corroborating evidence.
Given the absence of a plausible mechanistic rationale and the artefact-like scoring pattern, this prediction should not be interpreted as pharmacologically grounded without further independent validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Migalastat is not currently registered on the ARTG (Australian Register of Therapeutic Goods); no product entries are available.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 (model prediction only, no clinical trials or literature), and the identical TxGNN scores across the top five predicted indications indicate a likely graph-clustering artefact rather than a genuine mechanistic signal. Mechanism-of-action and safety data are also incomplete, so this candidate does not meet the threshold to proceed.
To proceed, the following is needed:
- Confirmed original-indication and mechanism-of-action data for migalastat (from DrugBank/PI, not inferred text)
- TFDA/TGA-approved Product Information for warnings, contraindications, and drug interactions
- Independent mechanistic assessment of why an α-Gal A chaperone would affect hepatoportal sclerosis pathology, given the current lack of biological rationale
- Investigation into whether the identical scores across ranks 1–5 reflect a TxGNN embedding artefact before further evidence collection is prioritised
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.